Hepatitis B virus drug resistance tools: One sequence, two predictions

23Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Drug resistance testing, genotype analysis, and the determination of immune and vaccine escape variants support personalized antiviral treatment for hepatitis B patients. As phenotypic drug resistance testing for hepatitis B virus (HBV) is especially labor-intensive, due to the lack of simple cell culture systems, genotypic methods play a very pronounced role. The genetic structure of HBV allows the simultaneous analysis of two different genes by examination of a single region in the genome of HBV. Nevertheless, the overlapping open reading frames of the hepatitis B surface antigen (HBsAg) and the reverse transcriptase (RT) have to be interpreted separately. In diagnostic procedures, standard Sanger type sequencing (mostly performed as a dye-dideoxynucleotide terminator system) is still the most commonly used method. This allows using established techniques for interpreting those types of genetic information. Besides reviewing the foundation of drug resistance interpretation for HBV, different interpretation systems, either commercially available (TRUGENE, Abbott, ViroScore) or free to use (geno2pheno[HBV], HIV-GRADE HBV tool), are compared in this article. © 2014 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Neumann-Fraune, M., Beggel, B., Kaiser, R., & Obermeier, M. (2014). Hepatitis B virus drug resistance tools: One sequence, two predictions. Intervirology, 57(3–4), 232–236. https://doi.org/10.1159/000361076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free